PRL and ovarian cancer: The ChIP analysis also confirmed the link between PRL and STAT3, with Bcl2a1a, Bcl2l2, and Birc5. STAT3 activation of Birc5 has been reported in paclitaxel- and cisplatin-resistant ovarian cancer cells, and the abrogation of STAT3 signaling results in a reduced expression of Birc5, circumventing chemoresistance [40,41].